Background
In this study, we aimed to present whether there was a significant difference between patients receiving 100 mg salicylate and not receiving salicylate before coronary artery bypass grafting in terms of amount of postoperative use of blood and blood products.
Methods
Sixty-one patients that underwent coronary bypass surgery in one year at our clinic were investigated retrospectively. Thirty (49.2%) of them were receivers of 100 mg entericcoated salicylate and 31 (50.8%) were non-receivers, divided into 2 groups. The mean age of salicylate receivers was 61.33 years whereas it was 57.71 years in the non-receivers.
Results
There was no significant difference between groups that underwent on-pump coronary bypass surgery in terms of mean units of blood and blood products used (p > 0.05). The percentage of blood product use was 54.5% in salicylate receivers and 55.6% in non-receivers. There was no significant difference between groups of patients that underwent off-pump beating heart coronary surgery in terms of amount of blood and blood product used (p > 0.05). The percentage of blood product use was 37.5% in salicylate receivers and 50% in non-receivers in this group of patients (p > 0.05).
Conclusions
When the amount blood and blood products used was investigated for patients undergoing either on-pump or off-pump coronary bypass in terms of salicylate use, no significant difference was detected between groups. 
